Previous 10 | Next 10 |
2024-04-23 08:17:15 ET More on pre-market losers & stocks. Affirm: Acceleration Across The Board Affirm Holdings: Hard To Win Against Block, PayPal And Klarna, Amid Substantial Losses Affirm: Stunning Acceleration In Growth And Margin Expansion (Rating Upgrade) ...
2024-04-23 05:15:48 ET More on related stocks: Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Nucor: A Solid Start To 2024 Novartis beats top-line and bottom-line...
2024-04-22 16:25:25 ET More on Abeona Therapeutics Abeona issues update on FDA market application for pz-cel Seeking Alpha’s Quant Rating on Abeona Therapeutics Historical earnings data for Abeona Therapeutics Financial information for Abeona Therapeut...
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies requested by FDA to support approval Anticipates completing and sub...
2024-04-16 21:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-07 00:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-19 06:53:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abeona Therapeutics (NASDAQ: ABEO ) just reported results for the fourth quarter of 2023. Abeona Therapeutics reported earnings per share of -64 cents. This was below the ...
2024-03-18 10:00:18 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
2024-03-18 07:41:37 ET More on Abeona Therapeutics Abeona issues update on FDA market application for pz-cel Abeona Therapeutics announces $50M credit facility Seeking Alpha’s Quant Rating on Abeona Therapeutics Historical earnings data for Abeona Ther...
CLEVELAND, March 18, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2023 and provided an update on progress toward achieving key corporate objectives. Abeona also announced today that the U.S. Food and Drug Administrati...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...